Carlsmed Raised $52.5M Series C for Revolutionary AI-Enabled Personalized Spine Surgery Platform
Carlsmed is a trailblazer in the field of personalized surgery.
Company Name: Carlsmed
Location: Carlsbad, CA
Sector: AI-Enabled Personalized Surgery Medtech
Funding Details: Raised $52.5M in Series C funding, led by B Capital and U.S. Venture Partners.
Purpose of Investment: To accelerate the commercialization of the aprevo® personalized spine surgery platform for lumbar fusion procedures and the development of aprevo® for cervical fusions, set to launch in 2025.
Leadership: CEO, Mike Cordonnier
“Our AI-enabled technology platform and innovative business model allows us to scale production rapidly to meet growing demand and empower patients.” Mike Cordonnie, CEO Carlsmed
Product: The aprevo® personalized surgery platform, developed by Carlsmed, is revolutionizing the standard of care in spine surgery. By leveraging AI, the platform offers tailor-made surgical solutions for individual patients, enhancing the precision and effectiveness of lumbar and, soon, cervical fusion procedures.
About Company: Carlsmed is a trailblazer in the field of personalized surgery. Its flagship product, the aprevo® platform, exemplifies its commitment to harnessing AI for medical advancements, offering unprecedented personalization in spinal surgeries. With a focus on both lumbar and upcoming cervical fusion applications, Carlsmed is poised to impact patient outcomes and the broader medical community significantly.